Challenges in the treatment of HIV and HCV coinfection

References

• Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J. Infect. Dis.192, 992–1002 (2005).
   PubMed Web of Science ®Google Scholar
• Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin. Infect. Dis.34, 831–837 (2002).
   PubMed Web of Science ®Google Scholar
• Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J. Hepatol.27, 18–24 (1997).
   PubMed Web of Science ®Google Scholar
• Saillour F, Dabis F, Dupon M et al. Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. Br. Med. J.313, 461–464 (1996).
   PubMedGoogle Scholar
• Browne R, Asboe D, Gilleece Y et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men: is sexual transmission feeding the increase? Sex. Transm. Infect.80, 326–327 (2004).
   PubMed Web of Science ®Google Scholar
• Gambotti L, Batisse D, Colin-de-Verdiere N et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France. Euro. Surveill.10, 115–117 (2001).
   Google Scholar
• Zanetti AR, Tanzi E, Paccagnini S et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet345, 289–291 (1995).
   PubMed Web of Science ®Google Scholar
• Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol.26, 1–5 (1997).
   PubMed Web of Science ®Google Scholar
• Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J. AIDS6, 602–610 (1993).
   PubMed Web of Science ®Google Scholar
• Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis.33, 562–569 (2001).
   PubMed Web of Science ®Google Scholar
• Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br. J. Haematol.87, 555–561 (1994).
   PubMed Web of Science ®Google Scholar
• Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS9, 1131–1136 (1995).
   PubMed Web of Science ®Google Scholar
• Sherman KE, O’Brien J, Gutierrez AG et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J. Clin. Microbiol.31, 2679–2682 (1993).
   PubMed Web of Science ®Google Scholar
• Bonacini M, Redeker AG. Intrahepatic HCV levels in chronic HCV infection. Gut45, 630–631 (1999).
   PubMedGoogle Scholar
• Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin. Infect. Dis.33, 240–247 (2001).
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Spengler U, Sudhop T et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am. J. Gastroenterol.91, 2563–2568 (1996).
   PubMed Web of Science ®Google Scholar
• Rosenthal E, Poiree M, Pradier C et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic study). AIDS17, 1803–1809 (2001).
   Web of Science ®Google Scholar
• Sanchez-Quijano A, Andreu J, Gavilan F et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur. J. Clin. Microbiol. Infect. Dis.14, 949–953 (1995).
   PubMed Web of Science ®Google Scholar
• Garcia-Samaniego J, Rodriguez M, Berenguer J et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am. J. Gastroenterol.96, 179–183 (2001).
   PubMed Web of Science ®Google Scholar
• Pineda JA, Romero-Gomez M, Diaz-Garcia F et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology41, 779–789 (2005).
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology30, 1054–1058 (1999).
   PubMed Web of Science ®Google Scholar
• Daar ES, Lynn H, Donfield S et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J. Infect. Dis.183, 589–595 (2001).
   PubMed Web of Science ®Google Scholar
• Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J. Infect. Dis.172, 1503–1508 (1995).
   PubMed Web of Science ®Google Scholar
• Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin. Infect. Dis.29, 150–154 (1999).
   PubMed Web of Science ®Google Scholar
• Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet356, 1800–1805 (2000).
   PubMed Web of Science ®Google Scholar
• Piroth L, Grappin M, Cuzin L et al. Hepatitis C virus coinfection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J. Viral Hepat.7, 302–308 (2000).
   PubMed Web of Science ®Google Scholar
• Kaufmann GR, Perrin L, Pantaleo G et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch. Intern. Med.163, 2187–2195 (2003).
   PubMed Web of Science ®Google Scholar
• Rockstroh JK. Influence of viral hepatitis on HIV infection. J. Hepatol.44, S25–S27 (2006).
   PubMed Web of Science ®Google Scholar
• Soriano V, Puoti M, Sulkowski M et al. Care of patients with hepatitis C and HIV coinfection. AIDS18, 1–12 (2004).
   PubMed Web of Science ®Google Scholar
• Flamm SL. Chronic hepatitis C virus infection. JAMA289, 2413–2417 (2003).
   PubMed Web of Science ®Google Scholar
• Trimoulet P, Neau D, Le Bail B et al. Intrahepatic HCV RNA loads in 37 HIV–HCV co-infected patients with controlled HIV infection. J. Med. Virol.67, 143–151 (2002).
   PubMed Web of Science ®Google Scholar
• Nelson M, Matthews G, Brook MG, Main J. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection. HIV Med.6(Suppl. 2), 96–106 (2005).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology35, 182–189 (2002).
   PubMed Web of Science ®Google Scholar
• Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS15, 1261–1268 (2001).
   PubMed Web of Science ®Google Scholar
• Puoti M, Bonacini M, Spinetti A et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J. Infect. Dis.183, 134–137 (2001).
   PubMed Web of Science ®Google Scholar
• Brau N, Salvatore M, Rios-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J. Hepatol.44, 47–55 (2006).
   PubMed Web of Science ®Google Scholar
• Tural C, Fuster D, Tor J et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J. Viral Hepat.10, 118–125 (2003).
   PubMed Web of Science ®Google Scholar
• Mehta S, Thomas D, Torbenson M et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology41, 123–131 (2005).
   PubMed Web of Science ®Google Scholar
• Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet362, 1708–1713 (2003).
   PubMed Web of Science ®Google Scholar
• Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS18, 2039–2045 (2004).
   PubMed Web of Science ®Google Scholar
• Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS20, 49–57 (2006).
   PubMed Web of Science ®Google Scholar
• Braitstein P, Palepu A, Dieterich D, Benhamou Y, Montaner JS. Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. AIDS18, 2221–2234 (2004).
   PubMed Web of Science ®Google Scholar
• Chung RT. Acute hepatitis C virus infection. Clin. Infect. Dis.41(Suppl. 1), S14–S17 (2005).
   Google Scholar
• Chung RT, Andersen J, Volberding P et al. Peginterferon Α-2a plus ribavirin versus interferon α-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med.351, 451–459 (2004).
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med.351, 438–450 (2004).
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon α-2b vs standard interferon α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA292, 2839–2848 (2004).
   PubMed Web of Science ®Google Scholar
• Laguno M, Murillas J, Blanco JL et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS18, F27–F36 (2004).
   Google Scholar
• Cargnel A, Angeli E, Mainini A et al. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir. Ther.10, 309–317 (2005).
   PubMed Web of Science ®Google Scholar
• Arends JE, Boucher CA, Hoepelman AI. Hepatitis C virus and human immunodeficiency virus coinfection: where do we stand? Neth. J. Med.63, 156–163 (2005).
   PubMed Web of Science ®Google Scholar
• Vogt MW, Hartshorn KL, Furman PA et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science235, 1376–1379 (1987).
   PubMed Web of Science ®Google Scholar
• Gries J, Torriani F, Rodriguez-Torres M et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV/HIV coinfection: final results of a randomized clinical study. Antimicrob. Agents Chemother.49(10), 3997–4008 (2005).
   PubMed Web of Science ®Google Scholar
• Nuñez M, Miralles C, Berdun M et al. The PRESCO study: role of extended therapy and/or optimal doses of ribavirin in the treatment of chronic hepatitis C in HIV-infected patients. 46th Inter Science Conference on Antimicrobial Agents and Chemotherapy. CA, USA, September 27–30 (2006) (In Press).
   Google Scholar
• Perez-Olmeda M, Nunez M, Romero M et al. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS17, 1023–1028 (2003).
   PubMed Web of Science ®Google Scholar
• Voigt E, Schulz C, Klausen G et al. Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. J. Infect.53, 36–42 (2006).
   PubMed Web of Science ®Google Scholar
• Dieterich D, Duff F, Sulkowski M et al. Sustained virologic response (SVR) in HIV-HCV co-infected patients with HCV genotype 1(G1) infection who have a rapid virological response (RVR) at week 4 of treatment with peginterferon α-2a (40KD) (PEG IFNα-2a, PEGASYS®) plus ribavirin (RBV, COPEGUS®): AIDS PEGASYS ribavirin international coinfection trial (APRICOT). 13th Conference on Retroviruses and Opportunistic Infections. CO, USA, February 5–8 (2006).
   Google Scholar
• Crespo M, Esteban J, Ribera E et al. Utility of the early virological response to individually adjust the duration of treatment for chronic hepatitis C, genotype 2 or 3, in HIV-coinfected patients. 13th Conference on Retroviruses and Opportunistic Infections. CO, USA, February 5–8 (2006).
   Google Scholar
• Zanini B, Puoti M, Quiros Roldan E et al. The optimal duration of treatment for HIV-infected patients with chronic hepatitis C (CHC) and genotype 2 or 3 is 48 weeks: results of a randomised controlled trial. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio De Janeiro, Brazil, July 24–27 (2005).
   Google Scholar
• Buti M, Valdes A, Sanchez-Avila F, Esteban R, Lurie Y. Extending combination therapy with peginterferon α-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology37, 1226–1227 (2003).
   PubMed Web of Science ®Google Scholar
• Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-α-2a plus ribavirin. Gastroenterology130, 1086–1097 (2006).
   PubMed Web of Science ®Google Scholar
• Fontana RJ. Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified? Gastroenterology130, 1357–1362 (2006).
   PubMed Web of Science ®Google Scholar
• Shiffman M, Pappas S, Nyberg L et al. PegInterferon α-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the ACCELERATE trial. 41st Annual Meeting of the European Association for the Study of the Liver (41st EASL). Vienna, Austria, April 26–30 (2006).
   Google Scholar
• Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J. Hepatol.42, 615–624 (2005).
   PubMed Web of Science ®Google Scholar
• Bani-Sadr F, Carrat F, Bedossa P et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS20, 525–531 (2006).
   PubMed Web of Science ®Google Scholar
• Haas DW, Lavelle J, Nadler JP et al. A randomized trial of interferon α therapy for HIV type 1 infection. AIDS Res. Hum. Retroviruses16, 183–190 (2000).
   PubMed Web of Science ®Google Scholar
• Soriano V, Sulkowski M, Bergin C et al. Care of patients with chronic hepatitis C and HIV coinfection: recommendations from the HIV-HCV International Panel. AIDS16, 813–828 (2002).
   PubMed Web of Science ®Google Scholar
• Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology36, S179–S184 (2002).
   Google Scholar
• Maida I, Soriano V, Gonzalez Lahoz J, Nunez M. Liver fibrosis stage in HIV/HCV-coinfected patients with persistently normal transaminases levels. 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, December 16–19 (2005).
   Google Scholar
• Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology128, 343–350 (2005).
   PubMed Web of Science ®Google Scholar
• Colletta C, Smirne C, Fabris C et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology42, 838–845 (2005).
   PubMed Web of Science ®Google Scholar
• Saito H, Tada S, Nakamoto N et al. Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatol. Res.29, 97–103 (2004).
   PubMed Web of Science ®Google Scholar
• Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut55, 409–414 (2006).
   PubMed Web of Science ®Google Scholar
• Nunes D, Fleming C, Offner G et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J. Acquir. Immune. Defic. Syndr.40, 538–544 (2005).
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Mehta S, Torbenson M, Moore RD, Thomas DL. Unexpected significant liver disease among HIV/HCV-coinfected persons with minimal fibrosis on initial liver biopsy. 12th Conference on Retrovirus and Opportunistic Infections (CROI). MA, USA, February, 22–25 (2005).
   Google Scholar
• McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology123, 1061–1069 (2002).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Dieterich DT, Bini EJ et al. Epoetin α once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J. AIDS39, 504–506 (2005).
   PubMed Web of Science ®Google Scholar
• Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann. Intern. Med.138, 187–190 (2003).
   PubMed Web of Science ®Google Scholar
• Schaefer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon α and ribavirin in psychiatric risk groups. Hepatology37, 443–451 (2003).
   PubMed Web of Science ®Google Scholar
• Mistler LA, Brunette MF, Marsh BJ, Vidaver RM, Luckoor R, Rosenberg SD. Hepatitis C treatment for people with severe mental illness. Psychosomatics47, 93–107 (2006).
   PubMed Web of Science ®Google Scholar
• Bani-Sadr F, Carrat F, Rosenthal E et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon–ribavirin combination treatment. Clin. Infect. Dis.41, 1806–1809 (2005).
   PubMed Web of Science ®Google Scholar
• Mauss S, Valenti W, DePamphilis J et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS18, F21–F25 (2004).
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Mats V, Walczak D. Systemic overview of HAART-associated liver enzyme elevations in patients infected with HIV and co-infected with HCV. 13th Conference on Retroviruses and Opportunistic Infections. CO, USA, February 5–8 (2006).
   Google Scholar
• Martin AM, Nolan D, James I et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS19, 97–99 (2005).
   PubMed Web of Science ®Google Scholar
• Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin. Trials4, 115–120 (2003).
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet363, 1253–1263 (2004).
   PubMed Web of Science ®Google Scholar
• Montessori V, Harris M, Montaner JS. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin. Liver. Dis.23, 167–172 (2003).
   PubMed Web of Science ®Google Scholar
• Puoti M, Bruno R, Soriano V et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS18, 2285–2293 (2004).
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Spengler U. HIV and hepatitis C virus coinfection. Lancet Infect. Dis.4, 437–444 (2004).
   PubMed Web of Science ®Google Scholar
• Miro JM, Montejo M, Rufi G et al. Liver transplantation in patients with HIV infection: a reality in 2004. Enferm. Infect. Microbiol. Clin.22, 529–538 (2004).
   PubMed Web of Science ®Google Scholar
• Vogel M, Voigt E, Schafer N et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort. Liver Transpl.11, 1515–1521 (2005).
   PubMed Web of Science ®Google Scholar
• Neff GW, Bonham A, Tzakis AG et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl.9, 239–247 (2003).
   PubMed Web of Science ®Google Scholar
• Jain AK, Venkataramanan R, Shapiro R et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl.8, 841–845 (2002).
   PubMed Web of Science ®Google Scholar
• Schonder KS, Shullo MA, Okusanya O. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann. Pharmacother.37, 1793–1796 (2003).
   PubMed Web of Science ®Google Scholar
• Vogel M, Voigt E, Michaelis HC et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl.10, 939–944 (2004).
   PubMed Web of Science ®Google Scholar
• Chalasani N, Manzarbeitia C, Ferenci P et al. Peginterferon α-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology41, 289–298 (2005).
   PubMed Web of Science ®Google Scholar
• Castells L, Vargas V, Allende H et al. Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J. Hepatol.43, 53–59 (2005).
   PubMed Web of Science ®Google Scholar
• Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon α-2b and ribavirin combination. J. Hepatol.40, 669–674 (2004).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Luna H, Khatib A, Sharma P et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α2b and ribavirin: an open-label series. Transplantation77, 190–194 (2004).
   PubMed Web of Science ®Google Scholar
• Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT. Pegylated interferon α-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin. Transplant.18, 166–173 (2004).
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of hepatitis C. Hepatology26, S62–S65 (1997).
   PubMedGoogle Scholar
• Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology125, 80–88 (2003).
   PubMed Web of Science ®Google Scholar
• Somsouk M, Lauer GM, Casson D et al. Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. Gastroenterology124, 1946–1949 (2003).
   PubMed Web of Science ®Google Scholar
• Gilleece YC, Browne RE, Asboe D et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J. Acquir. Immune Defic. Syndr.40, 41–46 (2005).
   PubMed Web of Science ®Google Scholar
• Luetkemeyer A, Hare CB, Stansell J et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J. Acquir. Immune. Defic. Syndr.41, 31–36 (2006).
   PubMed Web of Science ®Google Scholar
• Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon α-2b. N. Engl. J. Med.345, 1452–1457 (2001).
   PubMed Web of Science ®Google Scholar
• Vogel M, Bieniek B, Jessen H et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J. Viral Hepat.12, 207–211 (2005).
   PubMed Web of Science ®Google Scholar